SCHEMBL2945823

SCHEMBL2945823

CS(=O)(=O)N1CCN(c2nncc3cc(Br)ccc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 4/20 0.41
KMT2A Q03164 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
GBA1 P04062 2/20 0.40
CTSS P25774 1/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK1 P28482 1/20 0.38
NPY5R Q15761 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TSHR P16473 1/20 0.36
C1S P09871 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2954643 0.83 HRH4 (0.54) ALDH1A1LMNAKMT2AHRH4MAPT
SCHEMBL2947965 0.80 HPGD (0.46) ALDH1A1HSD17B10LMNAKMT2AHRH4
SCHEMBL2954669 0.78 SCN9A (0.46) ABL1BCRALDH1A1HSD17B10LMNA
SCHEMBL2954962 0.78 HTT (0.50) LMNAKMT2AHRH4
SCHEMBL2946003 0.78 MAPK14 (0.49) ALDH1A1HSD17B10LMNAKMT2AMAPT
SCHEMBL2947900 0.73 TSHR (0.46) ALDH1A1HSD17B10LMNAKMT2AKDM4E
SCHEMBL2953225 0.72 PRKCH (0.52) ALDH1A1LMNAKMT2AMAPTKDM4E
SCHEMBL2945156 0.72 LMNA (0.43) ALDH1A1LMNAKMT2AHRH4MAPT
SCHEMBL2952058 0.71 LMNA (0.45) LMNAKMT2AHRH4
SCHEMBL599751 0.68 LMNA (0.42) ALDH1A1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 ABL1 720/4885BCR 1184/4885ALDH1A1 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.